@article{0c4848aca2864f8f8102947496fccc0e,
title = "Are cancer patients at higher risk of death with covid-19?",
keywords = "Cancer, Coronavirus, COVID-19, MERS, SARS",
author = "Adashek, {Jacob J.} and Joud Hajjar and Chemaly, {Roy F.} and Razelle Kurzrock",
note = "Funding Information: Source of Support: JJA, None. JH has research funding from the Immune Deficiency Foundation, the Chao Physician Scientist Award, the Jeffery Modell Foundation, and Baxalta. RFC received research funding paid to his institution from Merck, Chimerix, Karius, Gilead, Ansun Biopharma, Viracor, Shire/Takeda, Oxford Immunotec, and Pulmotec and received honoraria from Merck, Chimerix, Shire/Takeda, Oxford Immunotec, Xenex, Ansun Biopharma, ReViral, Janssen, Pulmotec, and Kyorin. RK has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Boehringer Ingelheim, and Konica Minolta, as well as consultant and/or speaker fees from LOXO, X-Biotech, Actuate Therapeutics, Genentech, Pfizer, Roche, and NeoMed. Conflict of Interest: JJA has no disclosures. JH is a consultant for Taekeda. RK has an equity interest in IDbyDNA and Curematch, Inc., is a board member of CureMatch and CureMetrix, and a cofounder of CureMatch. Funding Information: Funded in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute Grant P30 CA023100 (RK).",
year = "2020",
doi = "10.4103/2666-2345.280883",
language = "English (US)",
volume = "3",
pages = "49--51",
journal = "Journal of Immunotherapy and Precision Oncology",
issn = "2666-2345",
publisher = "Innovative Healthcare Institute",
number = "2",
}